Search Our Site

With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for ‘anticompetitive’ dealmaking

With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for ‘anticompetitive’ dealmaking

Two pharma giants are squaring off a first-of-a-kind lawsuit over the budding biosimilar business in the U.S. Unable to make much headway with its first biosimilar rollout, Pfizer accuses Johnson & Johnson of striking “exclusionary contracts” on its megablockbuster Remicade to quash that competition. Filed Wednesday in Philadelphia federal court, Pfizer’s suit claims J&J’s contracting moves are anticompetitive, denying... Read More »

Read More →

Two pharma giants are squaring off a first-of-a-kind lawsuit over the budding biosimilar business in the U.S. Unable to make much headway with its first biosimilar rollout, Pfizer accuses Johnson & Johnson of striking “exclusionary contracts” on its megablockbuster Remicade to quash that competition. Filed Wednesday in Philadelphia federal court, Pfizer’s suit claims J&J’s contracting moves are anticompetitive, denying… Read More »

[...]

Read More

The continuing evolution of the Predict Suite of solutions from AMS has never been so evident with the latest and greatest updates and additions rolling out throughout this year. AMS continues to grow. We constantly strive to be better. AMS takes pride in our ability to quickly adapt and keep ahead of the competition. And… Read More »

[...]

Read More

Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers

Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too. At a time when the United States is in the grip of an opioid epidemic, many insurers are limiting access to pain medications that carry a lower risk of addiction or dependence, even... Read More »

Read More →

Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too. At a time when the United States is in the grip of an opioid epidemic, many insurers are limiting access to pain medications that carry a lower risk of addiction or dependence, even… Read More »

[...]

Read More

Casinos Aren’t Enough as Native Tribe Makes Deal on Drug Patents

For one Native American tribe, the money’s not in the casino anymore. Patents are the future. On Friday, drugmaker Allergan Plc said it would transfer intellectual property on a blockbuster drug to the Saint Regis Mohawk Tribe, in order to avoid attacks on the medicine’s patents. For the tribe, it’s a new revenue stream that... Read More »

Read More →

For one Native American tribe, the money’s not in the casino anymore. Patents are the future. On Friday, drugmaker Allergan Plc said it would transfer intellectual property on a blockbuster drug to the Saint Regis Mohawk Tribe, in order to avoid attacks on the medicine’s patents. For the tribe, it’s a new revenue stream that… Read More »

[...]

Read More

Read the Fine Print on the $475,000 Price of a Cancer Breakthrough

Novartis could have priced Kymriah much higher, and it’s being unusually flexible. Kicking it off, Gilead Sciences Inc. bought Kite Pharma Inc., a pioneer in “CAR-T” cell therapy, which uses a patient’s immune cells to potentially eradicate blood cancers with just one treatment. And on Wednesday, Novartis AG’s entry in this field, Kymriah, became the first such... Read More »

Read More →

Novartis could have priced Kymriah much higher, and it’s being unusually flexible. Kicking it off, Gilead Sciences Inc. bought Kite Pharma Inc., a pioneer in “CAR-T” cell therapy, which uses a patient’s immune cells to potentially eradicate blood cancers with just one treatment. And on Wednesday, Novartis AG’s entry in this field, Kymriah, became the first such… Read More »

[...]

Read More

‘Pen’ identifies cancer in 10 seconds

They say it could make surgery to remove a tumour quicker, safer and more precise. And they hope it would avoid the “heartbreak” of leaving any of the cancer behind. Tests, published in Science Translational Medicine, suggest the technology is accurate 96% of the time. The MasSpec Pen takes advantage of the unique metabolism of... Read More »

Read More →

They say it could make surgery to remove a tumour quicker, safer and more precise. And they hope it would avoid the “heartbreak” of leaving any of the cancer behind. Tests, published in Science Translational Medicine, suggest the technology is accurate 96% of the time. The MasSpec Pen takes advantage of the unique metabolism of… Read More »

[...]

Read More

Report: Drug company faked cancer patients to sell drug

Washington (CNN) – When Insys Therapeutics got approval to sell an ultra-powerful opioid for cancer patients with acute pain in 2012, it soon discovered a problem: finding enough cancer patients to use the drug. To boost sales, the company allegedly took patients who didn’t have cancer and made it look like they did. The drug... Read More »

Read More →

Washington (CNN) – When Insys Therapeutics got approval to sell an ultra-powerful opioid for cancer patients with acute pain in 2012, it soon discovered a problem: finding enough cancer patients to use the drug. To boost sales, the company allegedly took patients who didn’t have cancer and made it look like they did. The drug… Read More »

[...]

Read More

Will experimental blood test be a game-changer for Alzheimer’s disease?

An experimental blood test can accurately diagnose Alzheimer’s disease, the most common form of dementia, according to a study published Monday in the journal Proceedings of the National Academy of Sciences. Though still in development, the test may someday be used to diagnose other degenerative brain disorders and even mild cognitive impairment resulting from head... Read More »

Read More →

An experimental blood test can accurately diagnose Alzheimer’s disease, the most common form of dementia, according to a study published Monday in the journal Proceedings of the National Academy of Sciences. Though still in development, the test may someday be used to diagnose other degenerative brain disorders and even mild cognitive impairment resulting from head… Read More »

[...]

Read More

The Dawning of a New Era

by Alice Jamba, VP of Clinical Services, Advanced Medical Strategies On August 30, 2017, the FDA granted US approval to Kymriah (tisagenlecleucel), the first therapy based on gene transfer. Engineered chimeric antigen receptor T cell (CAR-T) treatment technology is designed to harness the power of a patient’s own immune system to effectively target and kill... Read More »

Read More →

by Alice Jamba, VP of Clinical Services, Advanced Medical Strategies On August 30, 2017, the FDA granted US approval to Kymriah (tisagenlecleucel), the first therapy based on gene transfer. Engineered chimeric antigen receptor T cell (CAR-T) treatment technology is designed to harness the power of a patient’s own immune system to effectively target and kill… Read More »

[...]

Read More

Zika virus selectively infects and kills glioblastoma cells in mice

The Zika virus (ZIKV) may infect and kill a specific type of brain cancer cells while leaving normal adult brain tissue minimally affected, according to a new study supported by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. In the paper, published online on September 5... Read More »

Read More →

The Zika virus (ZIKV) may infect and kill a specific type of brain cancer cells while leaving normal adult brain tissue minimally affected, according to a new study supported by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. In the paper, published online on September 5… Read More »

[...]

Read More

Page 1 of 36

Categories
Archives